Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Philadelphia Chromosome 2Translocation, Genetic 1Pathologic Processes 1Neoplasms by Histologic Type 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Leukemia 1Hematologic Diseases 1Bronchiolitis Obliterans Syndrome 1Bone Marrow Diseases 1

Interventions

Cytarabine 68Cyclophosphamide 44Methotrexate 41Daunorubicin 38Etoposide 34Vincristine 30Mercaptopurine 28Dexamethasone 24Radiotherapy 22Idarubicin 22Asparaginase 21Thioguanine 20Doxorubicin 19Prednisone 17Peripheral Blood Stem Cell Transplantation 17Imatinib Mesylate 16Busulfan 16pegaspargase 15Mitoxantrone 15Filgrastim 13Leucovorin 11fludarabine phosphate 10Hydrocortisone 10nilotinib 9Tretinoin 8Prednisolone 8Cyclosporine 8Hydroxyurea 7Epoetin Alfa 7Azacitidine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leukemia × bosutinib × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡